Back to Journals » Drug Design, Development and Therapy » Volume 14

Challenges for Mesenchymal Stem Cell-Based Therapy for COVID-19

Authors Li C, Zhao H, Wang B

Received 25 June 2020

Accepted for publication 6 September 2020

Published 29 September 2020 Volume 2020:14 Pages 3995—4001

DOI https://doi.org/10.2147/DDDT.S269407

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Yan Zhu


Chenghai Li,1,2,* Hua Zhao,3,4,* Bin Wang5

1Stem Cell Program of Clinical Research Center, Henan Provincial People’s Hospital and People’s Hospital of Zhengzhou University, Zhengzhou 450003, People’s Republic of China; 2Henan Key Laboratory of Stem Cell Differentiation and Modification, Zhengzhou 450003, People’s Republic of China; 3Reproductive Medicine Institute, Henan Provincial People’s Hospital and People’s Hospital of Zhengzhou University, Zhengzhou 450003, People’s Republic of China; 4People’s Hospital of Henan University, Zhengzhou 450003, People’s Republic of China; 5Department of Neurosurgery, Henan Provincial People’s Hospital and People’s Hospital of Zhengzhou University, Zhengzhou 450003, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Bin Wang; Chenghai Li Email bin.wang201166@hotmail.com; chenghai_li@yahoo.com

Abstract: The coronavirus disease 2019 (COVID-19) global pandemic continues and antiviral agents and vaccines are currently under investigation. Mesenchymal stem cell (MSC)-based therapy can be a suitable option for management of patients with COVID-19 at the urgent time of virus outbreak. Currently, MSCs are being explored against the novel infectious disease due to their therapeutic properties of anti-inflammation, immunomodulation and tissue repair and regeneration, albeit the precise mechanisms of MSC action toward COVID-19 remain unclear. To date, rigorous results from clinical trials using MSCs in human have been weakly positive. The pervasive uncertainty of using MSC therapeutic products as an effective combatant against COVID-19 requires rigorous resolution on several fronts, including MSC fate after infusion, safety issue, homing capability, and MSC resistance to the disease microenvironment. Focusing on these facets, a few important ones will be critically analyzed and addressed in this article for the development of safe and effective MSC-based therapies for COVID-19.

Keywords: COVID-19, mesenchymal stem cell, immunomodulation, tissue regeneration

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]